Holly K. Tabor, PhD and Aaron Goldenberg, PhD, MPH
Rare genetic disease research has something to teach precision medicine about addressing some patients’ limited access to treatment. Health disparities exacerbated by high costs and limited availability of drugs can, perhaps, be mitigated when patient activism accelerates drug development.
AMA J Ethics. 2018;20(9):E834-840. doi:
10.1001/amajethics.2018.834.
The allocation of scarce resources, such as HLA platelets, involves a conflict between the medical ethics principles of beneficence and social justice.
AMA J Ethics. 2016;18(8):764-770. doi:
10.1001/journalofethics.2016.18.8.ecas1-1608.
After years of funding disease-specific treatment, donation trends have shifted to support broader health systems infrastructure development. A remaining challenge is how to sustain antiretroviral therapy (ART) for patients in resource-poor regions.
AMA J Ethics. 2016;18(7):681-690. doi:
10.1001/journalofethics.2016.18.7.ecas3-1607.
This narrative information graphic contextualizes the lack of current maternal morbidity and mortality data in the United States since the Dobbs v Jackson Women’s Health Organization decision in 2022.
AMA J Ethics. 2024;26(1):E92-93. doi:
10.1001/amajethics.2024.92.
Dr Gillian R. Schmitz joins Ethics Talk to discuss her article, coauthored with Dr Robert W. Strauss: “What Should Students and Trainees Be Taught About Turfing and Where Patients Belong?”
Makenzie Doubek joins Ethics Talk to discuss her article, coauthored with Scott J. Schweikart: “Why Should Physicians Care About What Law Says About Turfing and Dumping Patients?”